Dynavax Technologies is pleased to cordially invite advocates, providers, patients and stakeholders committed to the elimination of hepatitis B virus (HBV) as a public health threat to participate in an educational webinar.
The webinar will be held on Wednesday, December 1st at 11:00am Pacific Time/ 2:00pm Eastern Time and will feature speakers from the Hepatitis B Foundation and Dynavax Technologies.
The CDC’s Advisory Committee on Immunization Practices (ACIP) voted on November 3rd to expand its adult HBV vaccination recommendation. As critical stakeholders and voices in the viral hepatitis community, we would like to update you on the impact of the new adult HBV vaccination recommendation. We will discuss the need for public health funding to achieve vaccination coverage for the expanded adult population, the need for expansion among existing adult hepatitis B vaccination programs and policies, and the need for an effective vaccine schedule to achieve HBV vaccination series completion.
HBV is preventable with effective vaccination. Having a recommendation for vaccinating an expansion in adults against HBV puts the U.S. on the path towards eliminating hepatitis B inequities. Together, we hope to advance actionable strategies to ensure successful adoption of the new ACIP adult HBV vaccination recommendation and to help meet U.S. goals to eliminate HBV as a public health threat by 2030.